HIV/AIDS Topics Dapivirine Vaginal Ring HIV Prevention Trial Launched in Africa
- Details
- Category: HIV Prevention
- Published on Wednesday, 20 June 2012 00:00
- Written by Press Release
The International Partnership for Microbicides (IPM) last week announced the start of large clinical trial testing whether a vaginal ring containing dapivirine can reduce women's risk of becoming infected with HIV.
U.S. Agencies Recommend Blunt Suture Needles to Reduce Risk of Viral Hepatitis and HIV
- Details
- Category: HIV Prevention
- Published on Tuesday, 12 June 2012 00:00
- Written by FDA
In late May, U.S. agencies concerned with worker health and safety issued a joint advisory recommending that healthcare personnel should use blunt-tip suture needles as an alternative to standard suture needles for stitching muscle and connective tissue, in order to decrease the risk of needle-stick injuries that could transmit blood-borne diseases such as hepatitis B, hepatitis C, and HIV.
African Study Finds HIV Superinfection May be as Common as Initial Infection
- Details
- Category: HIV Prevention
- Published on Friday, 08 June 2012 00:00
- Written by Liz Highleyman
HIV superinfection may occur much more often than previously believed, and in fact may occur about as often as first-time infections, according to a study from Uganda described in the June 15, 2012, advance online edition of the Journal of Infectious Diseases.
June 13: 'Rethinking MSM' Webinar on Politics of Identity in HIV Prevention
- Details
- Category: HIV Prevention
- Published on Tuesday, 12 June 2012 00:00
- Written by Press Release
On Wednesday, July 3, the HIV Prevention Justice Alliance (HIV PJA) will sponsor a webinar to examine the politics of identity definitions as they relate to HIV prevention, with an emphases on the category of "MSM," or men who have sex with men.
Raltegravir Shows Long-term Treatment Benefit, Appears Useful for Post-Exposure Prevention
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 30 May 2012 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) recently approved new product label information for raltegravir (Isentress), adding longer-term data showing that the drug remains effective for more than 3 years. In related news, researchers reported that raltegravir appears to be a good option for post-exposure prophylaxis (PEP) to prevent HIV infection.
Web Design and Development by